Has Pedro de la Rosa-Costa received payments from drug or device companies?

Yes. Drug and device makers reported $3,787 in general payments to Pedro de la Rosa-Costa across 132 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Pedro de la Rosa-Costa did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Pedro de la Rosa-Costa come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Pedro de la Rosa-Costa

Hematology & Oncology · Miami, FLNPI 1942277868

Payments from drug & device makers

$3,787in general payments, 2019–2025

Across 132 payments — averaging $28.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$369
Pharmacosmos Therapeutics Inc.$244
Merck$223
Bristol Myers Squibb$198
Sanofi$195
Pfizer$184
plus $2K from 42 others

What the payments were for

Food & beverage$3,67997%
Education$1073%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	10	$369
Pharmacosmos Therapeutics Inc.	5	$244
Merck	9	$223
Bristol Myers Squibb	8	$198
Sanofi	4	$195
Pfizer	8	$184
AstraZeneca(2 entities)	4	$171
Rigel Pharmaceuticals, Inc.	2	$141
Amgen	2	$131
Seagen Inc.	6	$123
Genentech USA, Inc.	6	$123
Myriad Genetic Laboratories, Inc.	2	$123
Novartis	4	$104
Incyte Corporation	4	$100
GSK	4	$97
Karyopharm Therapeutics Inc.	3	$82
Gilead	3	$80
Octapharma USA, Inc.	3	$79
Daiichi Sankyo Inc.	4	$75
AbbVie	3	$70
Jazz Pharmaceuticals Inc.	2	$64
EMD Serono, Inc.	3	$60
Johnson & Johnson	2	$52
Takeda Pharmaceuticals U.S.A., Inc.	2	$50
Mirati Therapeutics, Inc.	2	$50
E.r. Squibb & Sons, L.L.C.	2	$49
Astellas Pharma US Inc	2	$49
Taiho Oncology, Inc.	2	$42
Eisai Inc.	2	$41
Adaptive Biotechnologies Corporation	1	$31
Amneal Pharmaceuticals LLC	1	$27
Blue Earth Diagnostics	1	$26
Pharmacyclics LLC, An Abbvie Company	1	$25
Sobi, Inc	1	$24
Servier Pharmaceuticals LLC	1	$24
Genmab U.S., Inc.	1	$23
Morphosys, US Inc.	1	$23
Kyowa Kirin, Inc.	1	$22
Verity Pharmaceuticals Inc.	1	$22
Caris MPI, Inc.	1	$22
Bayer	1	$21
Deciphera Pharmaceuticals Inc.	1	$21
Boehringer Ingelheim	1	$20
G1 Therapeutics, Inc.	1	$20
Agios Pharmaceuticals, Inc.	1	$19
Beigene USA, Inc.	1	$19
ADC Therapeutics America, Inc.	1	$15
Exelixis Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,787 in reported general payments places this provider in the 35th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida →

Other hematology & oncology in Miami

Carl LandgrenMiami$47.8M
Dickran KazandjianMiami$8.4M
Justin WattsMiami$7.9M
Jaime MerchanMiami$7.9M
Frances ValdesMiami$5.7M
Manmeet AhluwaliaMiami$4.8M
Izidore LossosMiami$4.4M
Gerald SoffMiami$4.3M
James HoffmanMiami$3.3M
Ana Sandoval LeonMiami$3.2M

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →